Australia's CSL recovers after signing licensing deal with Eli Lilly

Csl

18/02/2026 24:32

** Shares of CSL CSL.AX rise 1.5% to A$153.78

** Shares rebound after plunging 16.9% last week on posting an 81% drop in first‑half profit, while CEO Paul McKenzie stepped down

** Australian biotech giant signs licensing agreement with Eli Lilly LLY.N, granting it certain rights to develop and commercialise clazakizumab

** Clazakizumab is an antibody aimed at preventing heart-related illness and death in people with end‑stage kidney disease

** CSL will receive an upfront payment of $100 million

** CSL shares down 10.9% YTD

(Reporting by Nichiket Sunil in Bengaluru)

((nichiket.sunil@thomsonreuters.com))